GLSI Greenwich LifeSciences Inc.: Earnings per share for the last 12 months

Greenwich LifeSciences Inc. (GLSI) - corporate logo

Geopolitical conflicts and sanctions are restricting access to global patient cohorts, hindering the drug development efforts of Greenwich LifeSciences (GLSI). The share price retrospective with the -10.00 metric demonstrates the impact of final-stage drug testing, toward which all of the company's capital is directed. Business protection is ensured by strict FDA oversight and exclusive vaccine patents, which create insurmountable barriers to entry for new market players.

Greenwich LifeSciences, Inc (GLSI) Net earnings per share (EPS TTM): for the period 02/11/2024 - 11/18/2026

Greenwich LifeSciences Inc - analytical breakdowns and key metrics (GLSI)

- current quotes and average value forecast:
Initial company analysis:Greenwich LifeSciences, Inc. GLSI
Product sample of Greenwich LifeSciences, Inc

Year-over-year (YoY) EPS growth (TTM) measures the rate of change in net income per share, comparing the current trailing twelve months to the previous period to identify actual capital efficiency. Investors utilize this metric to strip away GAAP paper adjustments from actual cash flow. The YoY EPS dynamics over the last 12 months help assess whether the reputation of Greenwich LifeSciences (GLSI) in the fight against breast cancer is backed by real financial growth. This protects capital from asset overvaluation based solely on patient hopes.